VRTX: Vertex Pharmaceuticals Forward P/E Multiple

Graphic logo of vrtx.com (VRTX)

Organic growth and the monopoly position of Vertex Pharmaceuticals (VRTX) drive the price action. The company's forward P/E ratio reflects the current business valuation, where 26.80 expresses the metric's value today. High margins are sustained by exclusive cystic fibrosis therapies. Stability is underpinned by robust scientific potential in CRISPR and the development of innovative drugs to combat severe pathologies.

vrtx.com - VRTX Price to Expected Earnings Ratio (period 07/04/2022 - 11/14/2026)

Vertex Corp (VRTX) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Price Chart Vertex|VRTX - Price Target Chart
- market capitalization information:
Market Capitalization Vertex Pharmaceuticals Incorporated|VRTX - Company Buyout Price
- book capitalization information:
Accounting Value per Share Vertex Pharmaceuticals|VRTX - Net Asset Value|Market Capitalization to Book Value Ratio vrtx.com|VRTX - Company Assets
- debt and liquidity details:
Total Debt to Capital Vertex Pharmaceuticals|VRTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Vertex Pharmaceuticals|VRTX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Vertex Pharmaceuticals Incorporated|VRTX - Long-Term Liabilities|Company Short-Term Debts Vertex Pharmaceuticals|Quick Ratio vrtx.com
- financial results and valuation multiples details:
VRTX - Net Profit|Expected Profit Vertex Pharmaceuticals|VRTX - Company Value to Net Income|Future Price to Earnings Vertex Pharmaceuticals Inc.|VRTX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Vertex Pharmaceuticals Incorporated|VRTX - Operating profit EBITDA|Net earnings per share for the last 12 months Vertex Pharmaceuticals|VRTX - Earnings per share for the last twelve months|Quarterly EPS earnings growth vrtx.com|VRTX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Vertex Pharmaceuticals
- sales and revenue indicators:
VRTX - Company Sales Revenue|Company Future Sales Volume Vertex|VRTX - Market Cap to Sales Volume|Forward P/S Multiple Vertex Pharmaceuticals Incorporated
Fundamental valuation:VRTX Vertex
Brand item of vrtx.com

For Vertex Pharmaceuticals (VRTX), the forward P/E chart reflects market expectations amid the patent protection of its unique drugs. This metric determines the capital payback period via the ratio of the current share price to expected earnings per share. It measures the premium investors are willing to pay for future cash flows. The issuer's monopoly status in rare disease therapy makes such multiples more resilient. The indicator's trend helps distinguish a fair premium from the onset of a long-term decline.

Competitor analysis for Vertex Pharmaceuticals

Future Price to Earnings Alnylam (ALNY)|Future Price to Earnings INSM (Insmed Inc.)|Forward P/E Multiple UTHR (United Therapeutics Corp.)|Market Cap to Projected Earnings BioMarin Corp (BMRN)|BBIO: Projected Price to Earnings|Price to Expected Earnings Ratio BGM|COGT: Forward P/E Multiple|Projected Price to Earnings Ratio Xeris Biopharma Holdings, Inc. (XERS)|KROS (Keros Pharma) - Forward P/E Multiple|Price to Future Earnings Ratio ARCT (Arcturus Corp)|Projected Price to Earnings ETON (Eton Pharmaceuticals)|KMDA (kamada.com) - Future Price to Earnings Multiple|Future Price to Earnings Fulcrum Therapeutics, Inc. FULC|ABEO (Abeona Therapeutics, Inc.) - Price to Expected Earnings Ratio|Mereo BioPharma Group PLC - Forward P/E Multiple|Future Price to Earnings Multiple PLX (Protalix BioTherapeutics, Inc)|PLRX: Forward P/E Multiple|appliedtherapeutics.com (APLT) - Forward P/E Multiple|Future Price to Earnings Rein Therapeutics|GELS: Future Price to Earnings Multiple|Future Price to Earnings Aytu BioPharma, Inc. (AYTU)|Projected Price to Earnings chemomab.com CMMB|Forward P/E Multiple SRXH (SRx Health Solutions)|Forward P/E Multiple Polyrizon Limited PLRZ|AEZS: Projected Price to Earnings|CYTH: Future Price to Earnings|INZY: Forward P/E Multiple|Projected Price to Earnings Ratio Reneo Pharmaceuticals, Inc (RPHM)|Future Price to Earnings COSCIENS Biopharma Inc.